Loading…
Loading…
CDTX (Cidara Therapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $220.52 and traded as high as $221.41. Cidara Therapeutics shares last traded at $221.38, with a volume of 2,691,000 shares. Analysts Set New Price Targets CDTX has
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 3,187 shares of the biotechnology company's stock, valued at approximately $305,000. Several other institutional investors and hedge funds also recently made changes to
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has assigned
HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million. The position represents 1.66% of 13F reportable assets under management (AUM).
Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) have received a consensus recommendation of "Hold" from the twelve research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have issued a buy recommendation and one has assigned
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.
Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) by 576.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 372,010 shares of the biotechnology company's stock after buying an additional 317,027 shares during the period.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for CDTX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.